Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer
Status:
Completed
Trial end date:
2017-10-19
Target enrollment:
Participant gender:
Summary
This is a clinical trial with a molecularly stratified parallel cohort, single arm design to
explore the efficacy and safety of BKM120 in combination with tamoxifen in patients with
ER/PR-positive, HER2-negative breast cancer with prior exposure to antihormonal therapy, and
different biomarker profiles, two of them potentially indicative of constitutive PI3K pathway
activation.